LPC-Degrading DeLCify Polypeptide for Inflammation Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to targeting lysophosphatidylcholine (LPC) for treating cardiovascular diseases, particularly atherosclerosis, have shown limited efficacy, as demonstrated by the failure of PLA2 inhibition strategies in reducing cardiovascular events and potentially increasing platelet-activating factor, highlighting the need for a new therapeutic approach.
Innovation Solution
Development of a polypeptide, DeLCify, with LPC-degrading activity, specifically designed to target and degrade LPC, including variants and fragments with sequences such as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, to treat cardiovascular diseases and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If PLA2 inhibition strategies are used to reduce LPC levels, then LPC-mediated inflammatory effects are reduced, but cardiovascular events are not reduced and platelet-activating factor increases
Solution Approach 1:
The patent extracts and removes LPC directly from the system using specific phospholipases (PLA1, PLA2, or Lp-PLA2) that degrade LPC into non-inflammatory products (free fatty acids and choline). This extraction approach bypasses the harmful effects of PLA2 inhibition while still achieving LPC reduction, thereby resolving the contradiction between reducing inflammatory effects and maintaining cardiovascular protection.
Solution Approach 2:
The patent changes the biochemical parameters by using alternative enzymatic pathways (PLA1 or Lp-PLA2) with different substrate specificities and product profiles compared to traditional PLA2 inhibition. This parameter change allows for LPC degradation that does not lead to platelet-activating factor accumulation, thus resolving the contradiction between reducing inflammation and preventing cardiovascular events.
2Object-affected harmful factors
If LPC levels are reduced through existing therapies, then some inflammatory effects are mitigated, but overall therapeutic efficacy is limited
Solution Approach 1:
The patent introduces specific phospholipases (PLA1, PLA2, or Lp-PLA2) as intermediary enzymes that mediate the conversion of LPC into non-inflammatory metabolites. These intermediaries provide a controlled and specific degradation pathway that enhances therapeutic efficacy by completely neutralizing LPC toxicity rather than merely reducing its levels, thereby resolving the contradiction between reducing inflammation and achieving reliable therapeutic outcomes.
3Object-affected harmful factors
If phospholipase enzymes are used to degrade LPC, then LPC toxicity is neutralized, but enzyme specificity and activity must be optimized
Solution Approach 1:
The patent segments the phospholipase enzyme family into distinct functional categories (PLA1, PLA2, and Lp-PLA2) with different substrate specificities and mechanistic properties. This segmentation allows for targeted selection of the most appropriate enzyme based on specific disease contexts and LPC profiles, reducing the complexity of enzyme optimization by providing clear guidelines for enzyme selection rather than requiring exhaustive testing of all phospholipases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DeLCify effectively degrades LPC, reducing its levels in animal models, thereby mitigating the progression of cardiovascular diseases and neurodegenerative disorders by neutralizing LPC toxicity and decreasing inflammatory responses.
Implementation Method 1
a polypeptide, DeLCify, with LPC-degrading activity, specifically designed to target and degrade LPC
Data Source
AI summary
The present invention related to a new polypeptide DeLCify with lysophosphatidylcholine (LPC)-degrading activity, which is effective in treating a disease or a disorder related to LPC, such as a cardiovascular disease or a neurodegenerative disease. Also provided is a method for the treatment of a disease or disorder related to LPC using the polypeptide DeLCify and a pharmaceutical composition comprising the polypeptide DeLCify.